Fundraising FoxOptiNose
Yardley, US · Delaware corporation · 3 known investors
Find your way into OptiNose
Sign up to see every warm intro you have to OptiNose
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OptiNose team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists. Its lead product, XHANCE (fluticasone propionate), uses the company's patented Bi-Directional Exhalation Delivery System (EDS) to deliver medication deep into the nasal passages.
Founders & leadership
MJ
Michele JanisExecutive
TT
Terrence TerifayExecutive
RM
Ramy MahmoudChief Executive Officer and Director2023–2025Ramy Mahmoud is a physician-scientist and CEO who co-founded OptiNose in 2010, serving as President/COO and later CEO while leading the company through drug development, FDA approval, IPO, and eventual sale to Paratek Pharmaceuticals. He previously spent 15 years at Johnson & Johnson in medical and scientific leadership roles, including Chief Medical Officer at Ethicon, and served as a U.S. Army officer and chief of epidemiology at the Walter Reed Army Institute of Research.
Board
KD
Klaas De BoerBoard director
SV
Sriram VenkataramanBoard director
WF
William F DoyleBoard director
JP
Jackson PhillipsBoard director
LP
Larry PickeringBoard director
PO
Patrick O'NeillBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$99.4M disclosed across 7 rounds · 2014–2024
▶$4.7MraisedMay 2024 · 2 investors · PharmaceuticalsRule 506(b)
▶$4.7MraisedMay 2024 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Paul SpenceExecutive Officer
- Catherine E. OwenDirector
- Wilhelmus GroenhuysenDirector
- Eric BednarskiDirector
- Tomas J. HeymanDirector
- Sandra L. HeltonDirector
- Kyle DempseyDirector
- Ramy A. MahmoudDirector, Executive Officer
- Michael F. MarinoExecutive Officer
- R. John FletcherDirector
- Anthony J. KrickExecutive Officer
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MraisedNov 2021 · 2 investors · PharmaceuticalsRule 506(b)
▶$4MraisedNov 2021 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter K. MillerExecutive Officer, Director
- Michael F. MarinoExecutive Officer
- Wilhelmus GroenhuysenDirector
- Keith GoldanExecutive Officer
- Tomas J. HeymanDirector
- Catherine E. OwenDirector
- Ramy A. MahmoudExecutive Officer
- Victor M. ClavelliExecutive Officer
- Joseph C. ScodariDirector
- Sandra L. HeltonDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedAug 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$250KraisedAug 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Victor ClavelliExecutive Officer
- Joshua A. TamaroffDirector
- Michael F. MarinoExecutive Officer
- Sriram VenkataramanDirector
- William F. DoyleDirector
- Joseph C. ScodariDirector
- Ramy A. MahmoudExecutive Officer
- Robert P. O'NeilDirector
- Sandra L. HeltonDirector
- Keith GoldanExecutive Officer
- Wilhelmus GroenhuysenDirector
- Catherine E. OwenDirector
- Peter K. MillerExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedSep 2019 · 2 investors · PharmaceuticalsRule 506(b)
▶$5.4MraisedSep 2019 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ramy A. MahmoudExecutive Officer
- Michael F. MarinoExecutive Officer
- Sriram VenkataramanDirector
- Robert P. O'NeilDirector
- Sandra L. HeltonDirector
- Wilhelmus GroenhuysenDirector
- William F. DoyleDirector
- Joseph C. ScodariDirector
- Keith GoldanExecutive Officer
- Peter K. MillerExecutive Officer, Director
- Joshua A. TamaroffDirector
- Offering amount
- $5.4M
- Amount sold
- $5.4M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedApr 2017 · 8 investors · Other Health CareRule 506(b)
▶$35MraisedApr 2017 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joshua TamaroffDirector
- Patrick O'NeillDirector
- William F. DoyleDirector
- Ramy MahmoudExecutive Officer
- Keith GoldanExecutive Officer
- Peter MillerExecutive Officer, Director
- Michael MarinoExecutive Officer
- Klaas De BoerDirector
- Per DjupeslandDirector
- Larry PickeringDirector
- Tom GibbsExecutive Officer
- Sriram VenkataramanDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedOct 2015 · 23 investors · Other Health CareRule 506(b)
▶$35MraisedOct 2015 · 23 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Per DjupeslandExecutive Officer, Director
- Michele JanisExecutive Officer
- Larry PickeringDirector
- Patrick O'NeillDirector
- Peter MillerExecutive Officer, Director
- Klaas De BoerDirector
- Terrence TerifayExecutive Officer
- Sriram VenkataramanDirector
- William F DoyleDirector
- Ramy MahmoudExecutive Officer
- Jackson PhillipsDirector
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedOct 2015 · 21 investors · Other Health CareRule 506(b)
▶$15MraisedOct 2015 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Larry PickeringDirector
- Patrick O'NeillDirector
- Ramy MahmoudExecutive Officer
- Terrence TerifayExecutive Officer
- Peter MillerDirector, Executive Officer
- Jackson PhillipsDirector
- Sriram VenkataramanDirector
- William F. DoyleDirector
- Klaas De BoerDirector
- Per DjupeslandExecutive Officer, Director
- Michele JanisExecutive Officer
- Offering amount
- $30M
- Amount sold
- $15M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through OptiNose went on to found or lead other companies.
Related companies · 2
OsmosisOsmosis is a US health education platform of short-form medical videos and learning tools, acquired by Elsevier.
MedscapeMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.
Companies working in the same space as OptiNose.
Frequently asked questions
- What does OptiNose do?
- Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists. Its lead product, XHANCE (fluticasone propionate), uses the company's patented Bi-Directional Exhalation Delivery System (EDS) to deliver medication deep into the nasal passages.
- Who founded OptiNose?
- OptiNose was founded by Per Djupesland.
- Who are OptiNose's investors?
- OptiNose's investors include Avista, Foresite Capital, MVM Life Science Partners.
- How much funding has OptiNose raised?
- OptiNose has disclosed $99.4M raised across 7 rounds.
- Where is OptiNose headquartered?
- OptiNose is headquartered in Yardley, US.